Table 1. Clinical manifestations in mice.
Mouse groupsa | ||||
---|---|---|---|---|
Normal group | Control APS group | Mock DNA vector-treated APS group | β2-GPI DNA vaccine-treated APS group | |
aPTT (seconds) |
29.4 ± 2.7** | 83.7 ± 14.8 | 77.4 ± 24.3 ns | 67.4 ± 23.6 ns |
Platelet count (×103 cells/mm3) |
684 ± 219* | 264 ± 144 | 244 ± 147ns | 338 ± 176ns |
% Fetal loss | 10 ± 9*** | 41 ± 19 | 45 ± 16 ns | 36 ± 18ns |
The data are presented as the means ± standard deviation of triplicate assays from 6–8 mice/group.
nsp>0.05,
*p<0.05,
**p< 0.01,
***p< 0.001 versus the control APS group.
anormal group, β2-GPI non-immunized mice; control APS group, saline-treated APS mice; mock DNA vector-treated APS group, mock plasmid-treated APS mice; β2-GPI DNA vaccine-treated APS group, β2-GPI DNA vaccine-treated APS mice.
APS, antiphospholipid syndrome; aPTT, activated partial thromboplastin time.